CannabisNewsBreaks – CV Sciences, Inc. (CVSI) Mines the Benefits of Science and Nature to Build Cannabidiol-Based Portfolio
The strategic integration of science and nature is the cornerstone of operations at CV Sciences (OTCQB: CVSI). Its Pharmaceuticals Division, for example, is developing synthetically formulated cannabidiol (CBD)‐based medicine for which the company is pursuing FDA approval. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions. The company’s initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. Focusing on enhancing the quality of life, CV Sciences’ Consumer Products Division delivers botanical-based CBD products such…